Ligand Pharmaceuticals Incorporated (LGND) Stock

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated (LGND) stock trades at $303.53 with a market capitalization of $6.05B. The stock is valued at a price-to-earnings (P/E) ratio of 31.21, price-to-book of 6.48, price-to-sales of 21.55. Over the past 52 weeks the stock has ranged between $175.56 and $326.63, and currently trades 7.1% below its 52-week high.

On profitability, Ligand Pharmaceuticals Incorporated generates a return on equity (ROE) of 20.06%, above the typical market range of roughly 12-15%, return on capital employed of 4.72%, an operating margin of 33.58%, a net profit margin of 67.88%.

Ligand Pharmaceuticals Incorporated by the numbers, 2016–2025

Between 2016 and 2025 Ligand Pharmaceuticals Incorporated reported revenue of $109.0M rising to $268.0M, a change of +145.9% across 10 years. Compounded, revenue has grown 10.3% a year over five years, 11.0% over three, 60.5% over the last twelve months. Net profit rose to $124.0M.

Operating margin went from 40.3% in 2016 to 17.6% in 2025, a fall of 22.7 percentage points. The most recent net margin is 67.88%. On a trailing twelve-month basis to Jun '26, revenue is $291.0M and net profit $198.0M.

Borrowings rose from $213.0M to $451.0M, cash from operations was $49.0M in the latest year, positive in 9 of the last 10.

Return on equity has averaged 4.1% over five years, and was 12.2% in the most recent year.

The share price itself has compounded at 23.5% a year over five years, 43.2% over three, 108.7% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Ligand Pharmaceuticals Incorporated (LGND) — frequently asked questions